Lipid measurements revealed that liver TG was unchanged in WT versus CD53 KO liver, although CD53-deficient mice were protected from NASH-D-induced liver cholesterol accumulation (Fig. 6F) in the absence of total NAFLD activity score changes, as assessed by treatment-blinded histopathology (Fig. S3). Here, CD53 is linked to metabolic dysfunction-associated steatohepatitis.